OABI Quote, Financials, Valuation and Earnings

GT Biopharma, Inc. has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of --. OmniAb, Inc.'s return on equity of -22.86% beat GT Biopharma, Inc.'s return on equity of -626.24%.

OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 294.27%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 1111.94%. Given that GT Biopharma, Inc. has higher upside potential than OmniAb, Inc., analysts believe GT Biopharma, Inc. is more attractive than OmniAb, Inc..

OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.172, suggesting its more volatile than the S&P 500 by 17.17%.

OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.

OmniAb, Inc. quarterly revenues are $2.2M, which are larger than GT Biopharma, Inc. quarterly revenues of --. OmniAb, Inc.'s net income of -$16.5M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 9.51x versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Karyopharm Therapeutics, Inc. has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of -75.21%. OmniAb, Inc.'s return on equity of -22.86% beat Karyopharm Therapeutics, Inc.'s return on equity of --.

OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 294.27%. On the other hand Karyopharm Therapeutics, Inc. has an analysts' consensus of $15.33 which suggests that it could grow by 135.17%. Given that OmniAb, Inc. has higher upside potential than Karyopharm Therapeutics, Inc., analysts believe OmniAb, Inc. is more attractive than Karyopharm Therapeutics, Inc..

OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Karyopharm Therapeutics, Inc. has a beta of 0.207, suggesting its less volatile than the S&P 500 by 79.284%.

OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Karyopharm Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. Karyopharm Therapeutics, Inc. pays out -- of its earnings as a dividend.

OmniAb, Inc. quarterly revenues are $2.2M, which are smaller than Karyopharm Therapeutics, Inc. quarterly revenues of $44M. OmniAb, Inc.'s net income of -$16.5M is higher than Karyopharm Therapeutics, Inc.'s net income of -$33.1M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while Karyopharm Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 9.51x versus 0.39x for Karyopharm Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of -301.29%. OmniAb, Inc.'s return on equity of -22.86% beat Nektar Therapeutics's return on equity of -327.67%.

OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 294.27%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 224.8%. Given that OmniAb, Inc. has higher upside potential than Nektar Therapeutics, analysts believe OmniAb, Inc. is more attractive than Nektar Therapeutics.

OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.

OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

OmniAb, Inc. quarterly revenues are $2.2M, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. OmniAb, Inc.'s net income of -$16.5M is higher than Nektar Therapeutics's net income of -$35.5M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 9.51x versus 36.33x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Recursion Pharmaceuticals, Inc. has a net margin of -738.05% compared to OmniAb, Inc.'s net margin of -3135.32%. OmniAb, Inc.'s return on equity of -22.86% beat Recursion Pharmaceuticals, Inc.'s return on equity of -80.23%.

OmniAb, Inc. has a consensus price target of $7.33, signalling upside risk potential of 294.27%. On the other hand Recursion Pharmaceuticals, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 62.04%. Given that OmniAb, Inc. has higher upside potential than Recursion Pharmaceuticals, Inc., analysts believe OmniAb, Inc. is more attractive than Recursion Pharmaceuticals, Inc..

OmniAb, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Recursion Pharmaceuticals, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

OmniAb, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Recursion Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OmniAb, Inc. pays -- of its earnings as a dividend. Recursion Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

OmniAb, Inc. quarterly revenues are $2.2M, which are smaller than Recursion Pharmaceuticals, Inc. quarterly revenues of $5.2M. OmniAb, Inc.'s net income of -$16.5M is higher than Recursion Pharmaceuticals, Inc.'s net income of -$162.3M. Notably, OmniAb, Inc.'s price-to-earnings ratio is -- while Recursion Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OmniAb, Inc. is 9.51x versus 39.63x for Recursion Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.